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Background: Patients receiving cancer treatment often have one or more co-morbid conditions that are
treated pharmacologically. Co-morbidities are recorded in clinical trials usually only at baseline.
However, co-morbidities evolve and new ones emerge during cancer treatment. The interaction between
multi-morbidity and cancer recovery is significant but poorly understood.
Purpose: To investigate the effect of co-morbidities (e.g. cardiovascular and diabetes) and medications
(e.g. statins, antihypertensives, metformin) on radiotherapy-related toxicity and long-term symptoms
in order to identify potential risk factors. The possible protective effect of medications such as statins
or antihypertensives in reducing radiotherapy-related toxicity will also be explored.
Methods: Two datasets will be linked. (1) CHHiP (Conventional or Hypofractionated High Dose Intensity
Modulated Radiotherapy for Prostate Cancer) randomised control trial. CHHiP contains pelvic symptoms
and radiation-related toxicity reported by patients and clinicians. (2) GP (General Practice) data from
RCGP RSC (Royal College of General Practitioners Research and Surveillance Centre). The GP records of
CHHiP patients will be extracted, including cardiovascular co-morbidities, diabetes and prescription
medications. Statistical analysis of the combined dataset will be performed in order to investigate the
effect.
Conclusions: Linking two sources of healthcare data is an exciting area of big healthcare data research.
With limited data in clinical trials (not all clinical trials collect information on co-morbidities or medica-
tions) and limited lengths of follow-up, linking different sources of information is increasingly needed to
investigate long-term outcomes. With increasing pressures to collect detailed information in clinical tri-
als (e.g. co-morbidities, medications), linkage to routinely collected data offers the potential to support
efficient conduct of clinical trials.
 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).erapy for
eralized
MA, Late
P, Royal
ncology
.
icr.ac.uk
signan),
6 A. Lemanska et al. / Technical Innovations & Patient Support in Radiation Oncology 2 (2017) 5–12Introduction
High doses of radiation are needed to cure most common can-
cers. Radiotherapy is planned with a ‘‘safety margin” to account
for any tumour or patient movement during treatment. This inevi-
tably leads to the inclusion of some healthy normal tissue in the
treatment target area which can lead to radiation damage and
side-effects [1]. Modern radiotherapy techniques can conform
radiation dose more precisely to fit the shape of the cancer. In addi-
tion the image-guidance methods make treatments more accurate.
These methods improve tumour targeting so they have signifi-
cantly reduced toxicity [2,3]. However, serious adverse-effects
and reduced quality of life (QOL) are still observed in a small num-
ber of patients [4–7]. Dose escalation to improve cancer cure can
also increase morbidity. Radiation side-effects and symptoms often
emerge many months or years after treatment (late-effects) and
may be difficult to investigate or manage.
Late-effects are a key concern to oncologists, as 84% of prostate
cancer (PCa) patients survive at least ten years [8] and avoidance of
long-term side-effects remains a clinical challenge. As the survival
rate is relatively high, PCa is now commonly described as a chronic
and slowly progressing disease. It is therefore crucial to under-
stand the long-term healthcare needs of this ageing population of
patients and the impact of co-morbidities in the management of
side-effects [9]. PCa is the most frequently diagnosed male cancer
in the United Kingdom (UK) with almost 50,000 new cases each
year [8]. External beam pelvic radiotherapy (EBRT) alongside sur-
gery is the main form of treatment and it is often used in conjunc-
tion with hormone therapy [10].
The most common side-effects of pelvic radiotherapy are those
experienced from gastrointestinal and genitourinary systems. The
most troublesome of the range of early reported short-term side-
effects are dysuria, haematuria, irritation and inflammation of
the skin, bowel, bladder or rectum. These side-effects are caused
directly by irradiation, and they usually improve quickly after
treatment [5,11]. Late side-effects occur from 6 months to several
years after treatment. The most common long-term side-effects
include urinary obstruction, incontinence, bowel frequency, procti-
tis and sexual problems [7,12–14]. These side-effects, similarly to
the short-term ones, are also caused by damage from the radiation
and the resulting vascular changes. However, they are usually
long-term and therefore have a significant impact on the QOL.
Inflammation is closely associated with increased acute toxicity,
and is also linked to late toxicity (as consequential late-effects)
[15]. The link of long-term side-effects with short-term is not fully
defined but short-term side-effects have been identified as a pre-
cursor of long-term [16]. For this reason it is important to act as
early as possible to prevent and reduce side-effects.
There are two areas of research that are of interest regarding co-
morbidities and concomitantmedications for cancer patients. One is
that co-morbidities result in worse health-related outcomes for
radiotherapy patients [2,3,17–20]. A recently completed systematic
literature review on radiotherapy in diabetic patients identified dia-
betes as a negative factor andhighlighted theneed formore research
[17]. Another stem of evidence leads to the effect of cardiovascular
medications and improved late toxicity [21–25]. Statins have been
found to improve health-related outcomes post-radiotherapy [26–
33]. Evidence suggests that those medications may protect against
normal tissue injury caused by radiation [27–31].
Materials and methods
Aims
The aim of this study is to investigate the effect of co-
morbidities (focusing on cardiovascular diseases and diabetes)and prescription medications (cardiovascular medications such as
statins, anticoagulants, heart medications, antihypertensives, erec-
tile dysfunction as well as diabetes medications e.g. metformin) on
symptoms and radiotherapy-related side-effects in PCa patients.
Two sources of healthcare data will be pulled together to study
long-term symptoms and toxicity in relation to co-morbidity. Gen-
eral Practice (GP) medical history will be extracted for CHHiP
patients. CHHiP (Conventional or Hypofractionated High Dose
Intensity Modulated Radiotherapy for Prostate Cancer,
CRUK/06/16) is a large PCa radiotherapy randomised controlled
trial (RCT) [34,35]. Patients recruited to CHHiP were randomised
to three different radiotherapy schedules and were monitored over
time. Therefore, long-term patient reported outcomes (PROs) and
clinician recorded radiotherapy-related symptoms and toxicity
data are available. The focus will be on urinary, rectal and sexual
symptoms and toxicity. The GP dataset that will be used is a data-
set of the Royal College of General Practitioners Research and
Surveillance Centre (RCGP RSC) [36].
Using de-identified (irreversibly hashed) NHS numbers (already
collected with consent in the CHHiP trial), GP records on co-
morbidities and prescription medications before, during, and after
radiotherapy will be retrieved for CHHiP patients. CHHiP prospec-
tively collected longitudinal data on radiotherapy-related symp-
toms and toxicity (follow-up up to 5 years) reported both by
patients (PROs) and clinicians. Table 1 details the type of data
extracted and linked from GP records and CHHiP trial. The resulting
linkeddatasetwill be used to investigate the effect of co-morbidities
and concomitant medications on symptoms and radiotherapy-
related side-effects.
Dataset
CHHiP clinical trial
CHHiP (CRUK/06/16, REC reference 04/MRE02/10) trial [34,35]
is conducted by the Institute of Cancer Research Clinical Trials
and Statistics Unit (ICR-CTSU). It is a dataset of 3216 men with
PCa recruited from 71 centres in the UK, Republic of Ireland,
Switzerland, and New Zealand between October 2002 and June
2011. Men were randomised to three different conformal Intensity
Modulated Radiotherapy (IMRT) dose schedules: the standard
schedule of 74 Gy (37 fractions(f)) given over 7.5 weeks, or two
hypofractionated and shorter schedules, doses of 60 Gy (20f) or
57 Gy (19f). The trial tested the hypothesis that hypofractionated
radiotherapy schedules for localised PCa would improve the thera-
peutic ratio by either improving tumour control or reducing nor-
mal tissue side-effects. It demonstrated non-inferiority of the
60 Gy/20f schedule (compared to 74 Gy/37f) in terms of biochem-
ical/clinical failure with similar and low rates of toxicity [34,35].
Patients were followed-up over time, and short-term and long-
term PROs and clinician-reported radiotherapy-related toxicity
data are available. The median follow-up of patients is 62.4 months
(IQR: 53.9–77.0). PROs were collected (as previously described
elsewhere [37,38]) with the UCLA Prostate Cancer Index (UCLA-
PCI) [39], Short Form (SF)-36 [40], and Functional Assessment of
Cancer Therapy-Prostate (FACT-P) [41] questionnaires. In March
2009 UCLA-PCI, FACT-P and SF-36 were replaced by the Expanded
Prostate Cancer Index Composite (EPIC) [42] and SF-12 [35]. Clini-
cian reported toxicity data were collected with the Radiation Ther-
apy Oncology Group (RTOG) [43], the Late Effects Normal Tissue
Toxicity; subjective, objective, management, and analytic (LENT/
SOMA) [44]. In this study, the focus is on symptoms and toxicity
in the three health domains (urinary, bowel and sexual) that are
most affected by PCa and its treatment.
Only the UK CHHiP population of patients (N = 3179) will be
included in this study. The non-UK patients will be excluded
because there are no NHS numbers for these patients. Patients
Table 1
Illustration of the type of data extracted and linked from (A) GP records and (B) CHHiP trial.
Source of
data
Type of data extracted Timelines
(A) RCGP RSC
GP records
Records of co-morbidities: Over time:
 cardiovascular conditions  from 3 months before the start of radiotherapy
 diabetes
Records of prescription medications
 during radiotherapy
 cardiovascular medications such as statins, anticoagulants, heart
medications, antihypertensives, erectile dysfunction medications
 after radiotherapy (all data that is available)
 diabetes medications eg. metformin
 antimuscarinics or alpha blockers
 rectal steroids
Records of hospital procedures (if recorded):
 cystoscopy
 TURP
 bladder neck incision
 salvage prostatectomy
 hip fracture
 hip replacement
 sigmoidoscopy
 colonoscopy
 argon laser coagulation
 hyperbaric oxygen
 records of prescribed incontinence pads
(B) CHHiP
clinical
trial
Patient and clinician-reported cancer and radiotherapy-related function,
symptoms, bother, QOL and toxicity for the following health domains:
Longitudinal, the following time points will be extracted:
 initial assessment - pre-hormone therapy (baseline)
 urinary  pre-radiotherapy
 rectal  10 weeks after the start of radiotherapy (acute)
 erectile
 general health
 every 6 months, up to 2 years after the start of radiotherapy
(long-term)
 physical function
(Detailed list of tools and specific domains is in Table 2)
 toxicity with RTOG collected weekly during radiotherapy and
then at 10, 12, 18 weeks and 12 months after radiotherapy
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will be included, even though the RCGP RSC contains records from
English GPs only. This is to create a nationally representative
resource. The RCGP RSC is representative of the whole UK
population [36]. To evaluate the representativeness of the linked
subsample, the analysis will include comparisons of linked records
to non-linked CHHiP patients and to the RCGP RSC population.
Another reason to include all the UK CHHiP patients is that there
are other GP databases (aside from RCGP RSC) that could be
linked to CHHiP as a follow-on from this project. This offers the
opportunity to follow-up patients from regions that are not
available in RCGP RSC. In addition, GP data may be available in
RCGP RSC for some of these patients if for example they had
previously been registered with an English GP.
In order to support the linkage of CHHiP to other data sources,
NHS numbers (CHI numbers in Scotland) were collected. Co-
morbidities were recorded at baseline and included diabetes,
hypertension, inflammatory bowel disease, previous pelvic sur-
gery, symptomatic haemorrhoids and previous TURP (transure-
thral resection of the prostate). With regard to prescription
medications, the information on a-blockers or anticholinergics
taken for bladder symptoms [Yes/No] was recorded. Table 2 illus-
trates the exact CHHiP data that will be used in this project.
RCGP RSC
The RCGP RSC [36] has been collecting primary care data in Eng-
land, and monitoring disease trends for almost 60 years. The net-
work of practices currently includes 192 GP practices with a total
number of about 1.5 million active patients (1.5% of the English
population). Data are extracted weekly from GP practices in the
network, covering the past 6 weeks of data. Every four months, a
bulk extract is conducted where historical data for all registered
patients are extracted. All patient personally identifiable data are
pseudonymised (de-identified) as close as possible to the point ofextraction from GP databases. The information that will be
extracted from GP records for CHHiP patients will include co-
morbidities (cardiovascular and diabetes) and medication history
taken for these conditions before, during and after radiotherapy.
Cardiovascular medications such as statins, anticoagulants, antihy-
pertensives, heart medications, erectile dysfunction as well as dia-
betes medicines such as metformin will be included. Table 1
summarises the type and time points of data extracted from both
sources. RCGP RSC has granted permission to conduct this project
(Data request RSC_0315). An NHS ethics approval has been
obtained from the West of Scotland REC1 (16/WS/0076).Study design
The study will be undertaken in the following four stages.De-identification (pseudonymisation) of CHHiP data
All patient personally identifiable data will be de-identified
before the transmission of CHHiP data to the University of Surrey.
NHS numbers will be hashed, dates of birth will be hashed, and
postcodes converted into Lower Super Output Areas (LSOAs) at
the ICR where the data is held. A hashing algorithm called Secure
Hash Algorithm 2 with 512 bit hash values (SHA2-512) will be
applied. NHS numbers and dates of birth in the RCGP RSC database
are already hashed using the same algorithm. Postcodes have also
been converted to LSOAs. This will facilitate the data linking pro-
cess without the need of any member of the research team at the
University of Surrey to access the patient identifiable information.
The SHA2-512 is a cryptographic hashing algorithm approved to
de-identify personal information. It uses asymmetric encryption
and is described as a one-way function, which means that it is
computationally impossible to generate the original data from
hashed values, even with the use of the secret key used for hashing.
Table 2
Illustration of data extracted from CHHiP dataset to be linked with GP records of CHHiP patients.
Information type Information retained in the study
Unique patient ID CHHiP study ID
Start of radiotherapy Date of start of radiotherapy
Personal identifiers for linking NHS numbers (hashed), date of birth (hashed), postcode (converted into Lower Super Output Areas (LSOA))
Randomisation group Standard schedule (control group): 74 Gy (37 fractions(f)); hypofractionated schedule 1: 60 Gy (20f); hypofractionated schedule 2:
57 Gy (19f)
Baseline information Recruitment centre, age, tumour stage, co-morbidities, previous TURP, medications
Source Tool Domain of health Timeline Scoring scale
PROs data SF-36 General Health, Physical Function Scales Initial assessment - pre-
hormone (baseline),
Pre-radiotherapy,
Scored on a Likert scale. Scores converted to
a 0–100 scale (0 representing worst outcome
and 100 representing best outcome).
SF-12
UCLA-PCI Urinary, Bowel and Sexual Domains 10 weeks after the start of
radiotherapy (acute),EPIC
FACT-P Additional Concern Scale (12 PCa and treatment
specific items)
Every 6 months after the start of
radiotherapy. Up to 2 years after
radiotherapy (long-term).Clinician
reported data
LENT/SOM Rectal, Bladder/Urethra, Sexual Dysfunction
Scales
Graded 0–4
RTOG (acute) Bladder and Bowel Weeks: 1–8, 10, 12 and 18 Graded 0–5
RTOG (late) Urinary Symptoms: Average daytime
frequency, Nocturia, Incontinence. Bowel
Symptoms: Frequency, Rectal bleeding. Erectile
Potency.
12 months
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Data for 3179 UK CHHiP participants, including study ID,
recruitment centre, hashed NHS numbers, hashed dates of birth,
LSOAs, age, randomization group, clinical baseline information
such as tumour stage, co-morbidities and medications, together
with symptoms and radiotherapy-related-toxicity recorded with
PROs and clinician-reported tools (see Table 2) will be transmitted
to the University of Surrey and stored on a secure server. Access to
data will be limited to the research team and will be password
controlled.Data linking
First, hashed NHS numbers will be used as a unique key to link
the two separate databases. For patients that cannot be linked
through this method, hashed dates of birth, the LSOA, and possible
diagnosis of prostate cancer will be explored as a secondary link-
age method. The information from the RCGP RSC records on the
number and type of co-morbid cardiovascular and diabetes condi-
tions as well as medications taken by CHHiP patients will be
extracted (see Table 1).Data analysis
To assess the value of the linked resource, statistical analysis of
the effect of co-morbidities and medications on patient- and
clinician-reported symptoms and radiotherapy-related toxicity
will be conducted. The number of CHHiP patients with co-morbid
conditions and the number and type of prescription medications
that patients take will be described. Medical history collected as
part of the CHHiP trial will be compared with that obtained from
the RCGP RSC. To investigate the representativeness of the linked
subsample, the incidence (proportion of patients with co-
morbidities and medications) in the RCGP RSC linked CHHiP sub-
sample will be compared to the overall CHHiP population and to
the RCGP RSC population. The occurrence and intensity of symp-
toms and radiotherapy-related toxicity in the RCGP RSC linked
CHHiP subsample will also be compared to the overall CHHiP pop-
ulation. The toxicity profiles of patients with co-morbidities and
medications will be compared to these of patients that do not have
specific co-morbidities or do not take medications to investigatethe effect. A detailed data analysis plan is described in section ‘Data
analysis’.
Data dictionary
A systematic literature review was conducted to gain under-
standing of which medications and co-morbidities interact with
radiotherapy, and what their impact on the side-effects from radio-
therapy may be. The literature review fed into the data dictionary
and the RCGP RSC extraction query will be based on knowledge
gathered during the literature review and consultations with clin-
icians. The data extraction will be defined as follows:
Co-morbidities and symptoms
The ontology was developed to extract the relevant co-
morbidities and symptoms from the RCGP database for CHHiP
patients. This allowed a conceptual map of symptoms, investiga-
tions, administrative codes, and diagnoses that can indicate a case
to be built [45]. For instance, a person with diabetes may not
always have a clear diagnosis code in the GP record, but they might
have administrative codes (diabetes review) or investigation codes
(HbA1c blood test results indicating diabetes), fromwhich it can be
inferred that the patient is a diabetes case.
Medications
A list of relevant medications was created based on sections 2
and 6.1 (drugs related to cardiovascular system and diabetes) of
the British National Formulary (BNF) (www.bnf.org). In the same
way as for co-morbidities and symptoms, the list of medications
was first developed, and then the list of related codes required
for data extraction was derived.
Statistical analysis
Standard descriptive statistics will be used to review the num-
ber of co-morbid conditions and prescription medications of CHHiP
patients for which RCGP RSC data are available. Baseline informa-
tion on co-morbidities and medications recoded in CHHiP will be
used to analyse the concurrence between the two data sources.
The McNemar test for paired data as well as proportional odds
logistic regression will be used to assess statistical significance of
CHHiP dataset RCGP RSC data
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Fig. 1. The plan of data analysis.
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those revealed in RCGP RSC data. A chi-squared (v2) test will be
used to compare the incidence (proportions) of co-morbidities in
the RCGP RSC linked CHHiP subsample and in the overall CHHiP
sample and RCGP RSC population.
Using the information on symptoms and radiotherapy-related
toxicity recorded in CHHiP, the occurrence and intensity in the
overall CHHiP population and in the RCGP RSC linked subsample
will be described. The homogeneity of the RCGP RSC linked CHHiP
subsample will be assessed with a v2 test. Logistic regression will
be applied to relate the information on occurrence and intensity of
symptoms and radiotherapy-related toxicity to co-morbidities and
prescription medications. This will be done to investigate the effect
of co-morbidities and medications on symptoms and toxicity. The
levels of symptoms and toxicity will be summarised for people
with particular co-morbid conditions. This information will be
compared to people without co-morbidities and to the general
CHHiP population to assess if patients with co-morbidities have
higher or lower toxicity levels. Information on particular medica-
tions such as statins or ACE-inhibitors taken by patients before,
during and after radiotherapy will be used to investigate the effect
of these medications on symptoms and toxicity. The information
on each of the medications (by a pharmacological group) will be
used as a binary item in the logistic regression. The plan of data
analysis is illustrated in Fig. 1.
Age is a well recognized confounding factor [2,46], and there-
fore the modelling of radiotherapy-related symptoms and toxicity
will be adjusted for age. The regression analysis will also be
adjusted for the effect of the CHHiP randomisation group. Methods
based on multilevel analysis of variance (ANOVA) will be used to
model the effect of co-morbidities and medications on the devel-
opment of symptoms and toxicity over time. Those methods pro-vide a variance split in the data according to the contribution of
experimental factors [47]. The effect of co-morbidities or medica-
tions over time will be isolated and assessed without confounding
factors such as age or randomisation group. If feasible and accord-
ingly to the success of data linkage, Generalized Estimating Equa-
tions (GEE) [48] will also be used. This is an approach developed
for the longitudinal nested data. It allows for the inclusion of cate-
gorical as well as continuous variables and for variable selection
procedures in order to select the best model [49]. Regression
parameters can be calculated for each point in time. Therefore
the effect of co-morbidities and medications on acute symptoms
can be compared to that on long-term effects.Discussion
EBRT can lead to functional and structural damage that can
cause long-term symptoms. The accumulation of radiation in the
tissues results in DNA damage and changes in the cellular micro-
environment, mainly via cytokines-inflammatory pathways. The
process of cell reparation and restoration is similar to that of
wound healing [50]. However, repetitive injury during the course
of radiation can lead to scaring which in the long-term manifests
as fibrosis, atrophy and vascular damage [51,52]. Potential cellular
and vascular changes that impact on the side-effects from radio-
therapy are not fully explained. The evidence regarding the effect
of co-morbidities and medications on these cellular and vascular
changes is also conflicting but some studies suggest that concomi-
tant medications may affect the inflammatory response induced by
radiotherapy. Cardiovascular medications change inflammatory
responses and microvasculature and it is believed that through
these mechanisms they impact on radiation toxicity [29,33].
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treatment. Fibrosis reduces the elasticity and vascularisation of tis-
sues and organs such as the bladder or bowel, and this leads to
lasting side-effects [53–56]. Research shows that the occurrence
and severity of long-term side-effects depends on multiple treat-
ment factors such as the type of treatment, radiation total dose,
dose per fraction [17,57–59] and the type of irradiated tissue
[60,61]. Late side-effects are associated with age, baseline patient
characteristics and intensity of baseline symptoms and short-
term side-effects. Recent studies also recognised mechanisms of
genetic risk factors [62]. In addition, patients with co-morbid con-
ditions are at a higher risk than others [63–65]. Risk of fibrosis is
higher in patients with hypertension or diabetes due to changes
in microvasculature, or with scleroderma due to collagen over
expression [66]. Despite our increasing knowledge of these risk
factors, it is still difficult to predict the occurrence of fibrosis and
late-effects in patients. However, exploring co-morbidities and
medication use may be of benefit because of the role that they play
during regenerative processes and the effect on inflammation,
microvascular damage, or hypoxia.
The research into the risk factors has produced conflicting evi-
dence but some studies show that cardiovascular medications
taken by patients to control their co-morbidities may reduce
radiotherapy-related toxicity [21,23,24]. The mechanisms are not
fully established but it is believed that improving the cardiovascu-
lar flow of the healthy tissue surrounding tumours may reduce
the inflammatory response that is responsible for many of the
side-effects, and so those medications may protect against normal
tissue injury caused by radiation. The evidence to support this
association is limited and there is a need for more research.
Data linkage techniques are increasingly being used to create
comprehensive datasets that can be used to explore specific issues
or search for evidence that could not be investigated in the limited
data available from isolated studies. Despite the clear potential and
increasing patient benefit, this type of research is still hampered by
serious governance and data protection issues. To address patient
confidentiality concerns, an established method of data linkage
has been used. This method has been deemed adequate by the
NHS Research Ethics Committee who approved the project. Inevita-
bly NHS numbers are required for linking large datasets such the
two used in this study. However, themethod of irreversible hashing
of NHS numbers that will be applied here, protects patients’ privacy
while at the same time allowing for effective data linkage. Facilitat-
ing data sharing across healthcare settings and data linkage across
studies is supported by the Department of Health information strat-
egy [67]. Some examples of benefits to patients include better plan-
ning of NHS resources or improved healthcare services as well as
improved patient health-related outcomes.
The RCGP RSC database was used because due to the regular
data extractions it is one of the most up to date GP databases in
the UK. It currently covers 2.8% of the English population but it
continues to expand its GP network. Based on these values, the
estimated number of GP records that may be available for CHHiP
patients is 89. It is a relatively small number and this could poten-
tially hinder the statistical analyses that are planned for this pro-
ject. This is a serious concern and a limitation of this study.
There are other GP databases that could be used to extract GP
records for CHHiP patients so there is potential to build on this pro-
ject. They could be linked to CHHiP to trace more patients and
increase the quality of the evidence. In the current project a suffi-
cient statistical power may not be reached due to potentially a
small proportion of linked patients. However, the contribution of
this project is still considered important. In particular, the success
of the linkage process can be investigated. The evidence regarding
linking clinical trials and GP data is limited and CHHiP has never
been used in this kind of research.The systems are not in place to routinely link clinical trials with
GP data. However, there are clear benefits for health research and
clinical practice. They include a support of efficient conduct of clin-
ical trials and opportunities for a long-term follow-up even after a
clinical trial has ended. The information on co-morbidities or pre-
scription medications is important, but not always collected within
clinical trials. It could therefore be obtained via linkage from other
sources. However, in order to ensure that the opportunities of data
linkage are maximised and that the evidence derived from the
linked resources is reliable, we need to better understand the
requirements and implications of data linkage. This project will
contribute to the knowledge providing the evidence with regard
to risks and benefits of linking clinical trials and GP data. The pro-
cess of GP data extraction will be tested and an insight generated
on how this combined resource could be used to supplement infor-
mation collected within clinical trials.Conclusions
GP records will be extracted for CHHiP patients to investigate
the effect of co-morbidities and prescription medications on the
development of symptoms and on radiotherapy outcomes. This is
a truly current approach as in the past the research mainly focused
on exploring treatment factors and baseline patient characteristics.
At present there is only limited evidence on the effect of medica-
tions taken for co-morbid conditions in cancer patients. Methods
of reducing side-effects of radiotherapy by pharmacologically pro-
tecting normal tissue against damage from radiation have not yet
been extensively explored.
The reduction of treatment side-effects has become a key chal-
lenge in modern radiotherapy as patients survive many years post
treatment. The population of cancer patients is ageing and the
complexity of risk factors for radiotherapy-related side-effects
increases due to the high prevalence of multi-morbidity. Therefore
investigating the effect that co-morbidities and medications taken
during radiotherapy may have on radiotherapy-related toxicity
requires more research. This research is of high relevance to
patients and could potentially lead to improved health-related out-
comes post-radiotherapy. To optimise the management of people
treated with radiotherapy an understanding is required of how to
account for multi-morbidity and its effect during treatment plan-
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